Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Chemotherapy Resistance and Sensitivity Testing in Lung Tumors|
- Tumor size [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start.
Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay.
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory.
The drug screening assay will be used to evaluate the response of the CSCs and of the cancer cells to the various chemotherapy regimens.
|Contact: Pier P. Claudio, M.D., Ph.D.||firstname.lastname@example.org|
|United States, West Virginia|
|Cabell Huntington Hospital||Recruiting|
|Huntington, West Virginia, United States, 25701|
|Contact: Rajesh Sehgal, M.D. 304-399-6551 email@example.com|
|Sub-Investigator: Rajesh Sehgal, M.D.|
|Sub-Investigator: Michael V. Korona, M.D.|
|Principal Investigator:||Pier P. Claudio, M.D., Ph. D||Marshall University School of Medicine|